Glycomine Inc.
We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
Glycomine Inc. Offices
OnSite Workspace
Employees work from physical offices.
Typical time on-site:
None
San Carlos, California, USA
.png)

